Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling

Carcinogenesis

Volumn 34, Issue 3, 2013, Pages 638-646

  Wang, Zi Li ^a   Fan, Zhi Qiang ^a   Jiang, Han Dong ^b   Qu, Jie Ming ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; ETODOLAC; MITOGEN ACTIVATED PROTEIN KINASE; SMAD PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOGS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; LUNG NEOPLASMS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; RNA, SMALL INTERFERING; SMAD PROTEINS; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84874773523     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs367     Document Type: Article

References (38)

1. Fong, Y.C. et al. (2009) Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells. Lung Cancer, 64, 13-21.
2. Inamura, K. et al. (2010) Lung cancer progression and metastasis from the prognostic point of view. Clin. Exp. Metastasis, 27, 389-397.
3. Jemal, A. et al. (2008) Cancer statistics, 2008. CA. Cancer J. Clin., 58, 71-96.
4. Louie, A.V. et al. (2009) Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. Clin. Lung Cancer, 10, 174-179.
5. Tsuchiya, T. et al. (2007) Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer, 56, 341-348.
6. Jonnalagadda, S. et al. (2011) The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer. Chest, 140, 433-440.
7. Smith, W.L. et al. (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem., 69, 145-182.
8. Lim, B.J. et al. (2010) Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance. Mol. Med. Report., 3, 43-49.
9. Lee, J.M. et al. (2007) Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncol., 3, 149-153.
10. Jang, T.J. et al. (2009) Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers. Yonsei Med. J., 50, 818-824.
11. Voulgari, A. et al. (2009) Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta, 1796, 75-90.
12. Ogunwobi, O.O. et al. (2011) Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin. Exp. Metastasis, 28, 721-731.
13. Neil, J.R. et al. (2008) Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis, 29, 2227-2235.
14. Gadgeel, S.M. et al. (2007) Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J. Thorac. Oncol., 2, 299-305.
15. Agarwala, A. et al. (2008) Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. J. Thorac. Oncol., 3, 374-379.
16. Koch, A. et al.; Swedish Lung Cancer Study Group. (2011) Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur. J. Cancer, 47, 1546-1555.
17. Ai, J. et al. (2011) The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma. J. Natl. Cancer Inst., 103, 1696-1712.
18. Kasai, H. et al. (2005) TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir. Res., 6, 56.
19. Kessenbrock, K. et al. (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 141, 52-67.
20. Yu, L. et al. (2011) Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation. Mol. Pharmacol., 79, 608-617.
21. Zhao, X. et al. (2008) Cyclooxygenase-2 expression during immortalization and breast cancer progression. Cancer Res., 68, 467-475.
22. Noda, M. et al. (2002) Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines. J. Gastroenterol., 37, 896-904.
23. Okamoto, A. et al. (2008) Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology, 71, 156-160.
24. Kato, T. et al. (2011) Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: a novel cyclooxygenase-inhibition-independent effect. Biochem. Pharmacol., 82, 1781-1791.
25. Fidler, M.J. et al. (2008) The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin. Cancer Res., 14, 2088-2094.
26. Fabi, A. et al. (2008) Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemother. Pharmacol., 62, 717-725.
27. Rini, B.I. et al. (2006) Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer, 106, 566-575.
28. Edelman, M.J. et al. (2008) Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J. Clin. Oncol., 26, 848-855.
29. Park, S.W. et al. (2010) Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines. Anticancer. Drugs, 21, 823-830.
30. Chen, S. et al. (2011) Celecoxib promotes c-FLIP degradation through Aktindependent inhibition of GSK3. Cancer Res., 71, 6270-6281.
31. Guruswamy, S. et al. (2009) Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention. Int. J. Oncol., 35, 1037-1043.
32. Xia, S. et al. (2010) Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. Cancer Biother. Radiopharm., 25, 317-323.
33. Niederberger, E. et al. (2001) Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J., 15, 1622-1624.
34. Mendoza, M.C. et al. (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci., 36, 320-328.
35. Yu, C.F. et al. (2002) ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase. J. Biol. Chem., 277, 19382-19388.
36. Yoon, Y.K. et al. (2009) Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol. Cancer Ther., 8, 2526-2536.
37. Yoon, Y.K. et al. (2010) KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol. Carcinog., 49, 353-362.
38. Moelling, K. et al. (2002) Regulation of Raf-Akt Cross-talk. J. Biol. Chem., 277, 31099-31106.